Expression of nephronectin is inhibited by oncostatin M via both JAK/STAT and MAPK pathways  by Kurosawa, Tamaki et al.
FEBS Open Bio 5 (2015) 303–307journal homepage: www.elsevier .com/locate / febsopenbioExpression of nephronectin is inhibited by oncostatin M via both
JAK/STAT and MAPK pathwayshttp://dx.doi.org/10.1016/j.fob.2015.04.001
2211-5463/ 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: Npnt, nephronectin; OSM, oncostatin M; JAK, janus kinase; STAT,
signal transducer and activator of transcription; MAPK, mitogen-activated protein
kinase; MAM, meprin, A5 protein, and receptor protein-tyrosine phosphatase l;
OSMR, OSM receptor; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-
terminal kinase; TGF-b, transforming growth factor-b; TNF-a, tumor necrosis
factor-a; BMP-2, bone morphogenetic protein-2; MEF2, myocyte enhancer-binding
factor 2A
⇑ Corresponding author at: Department of Biochemistry, School of Dentistry,
Showa University, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8555, Japan. Tel.: +81 3
3784 8163; fax: +81 3 3784 5555.
E-mail address: yamadaa@dent.showa-u.ac.jp (A. Yamada).Tamaki Kurosawa a,b, Atsushi Yamada a,⇑, Masamichi Takami c, Dai Suzuki a, Yoshiro Saito a,d,
Katsuhiro Hiranuma a,e, Takuya Enomoto a,f, Naoko Morimura g, Matsuo Yamamoto f, Takehiko Iijima e,
Tatsuo Shirota d, Hiroyuki Itabe b, Ryutaro Kamijo a
aDepartment of Biochemistry, School of Dentistry, Showa University, Shinagawa, Tokyo 142-8555, Japan
bDivision of Biological Chemistry, Department of Molecular Biology, Showa University School of Pharmacy, Shinagawa, Tokyo 142-8555, Japan
cDepartment of Pharmacology, School of Dentistry, Showa University, Ohta, Tokyo 145-8515, Japan
dDepartment of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, Ohta, Tokyo 145-8515, Japan
eDepartment of Perioperative Medicine Division of Anesthesiology, School of Dentistry, Showa University, Ohta, Tokyo 145-8515, Japan
fDepartment of Periodontology, School of Dentistry, Showa University, Ohta, Tokyo 145-8515, Japan
gBrain Science Laboratory, The Research Organization of Science and Technology, Ritsumeikan University, Kusatsu, Shiga 525-8577, Japana r t i c l e i n f o
Article history:
Received 10 November 2014
Revised 30 March 2015
Accepted 1 April 2015
Keywords:
Nephronectin
Oncostatin M
JAK/STAT
MAPKa b s t r a c t
Nephronectin (Npnt), also called POEM, is an extracellular matrix protein considered to play critical
roles as an adhesion molecule in the development and functions of various tissues, such as the kid-
neys, liver, and bones. In the present study, we examined the molecular mechanism of Npnt gene
expression and found that oncostatin M (OSM) strongly inhibited Npnt mRNA expression in
MC3T3-E1 cells from a mouse osteoblastic cell line. OSM also induced a decrease in Npnt expression
in both time- and dose-dependent manners via both the JAK/STAT and MAPK pathways. In addition,
OSM-induced inhibition of osteoblast differentiation was recovered by over-expression of Npnt.
These results suggest that OSM inhibits Npnt expression via the JAK/STAT and MAPK pathways, while
down-regulation of Npnt by OSM inﬂuences inhibition of osteoblast differentiation.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nephronectin (Npnt), an extracellular matrix protein identiﬁed
as a ligand that mediates the function of integrin a8b1 in develop-
ing kidneys, has 5 EGF-like domains, an Arg-Gly-Asp (RGD) cell
binding motif, and MAM domain [1,2]. This protein also has critical
roles in other tissues, such as kidney development [3], exacerba-
tion of hepatitis [4], and promotion of osteoblast differentiation
[5,6].MC3T3-E1 cells are used for in vitro bone model of development
systems, in which 2 time-dependent developmental sequences,
proliferation and differentiation of osteoblasts are observed [6].
Kahai et al. found that when MC3T3-E1 cells were stably trans-
fected with a small interfering RNA (siRNA) plasmid for inhibition
of Npnt gene expression, osteoblast differentiation was inhibited,
whereas over-expression of Npnt promoted osteoblast differentia-
tion [6]. Other studies have also demonstrated that TGF-b inhibits
Npnt expression in both time- and dose-dependent manners, while
Npnt-induced osteoblast differentiation was shown to be inhibited
by TGF-b in MC3T3-E1 cells [7,8]. Similarly, TNF-a inhibits Npnt
expression in both time- and dose-dependent manners, and
down-regulation of Npnt inﬂuences inhibition of osteoblast dif-
ferentiation by TNF-a [7,9].
Oncostatin M (OSM) is a cytokine and member of the inter-
leukin (IL)-6 subfamily that includes IL-6, leukemia inhibitory
factor (LIF), ciliary neurotrophic factor (CNTF), IL-11, car-
diotrophin-like cytokine (CLC), cardiotrophin-1 (CT-1), and novel
neurotrophin-1/B cell stimulating factor-3 (NNT-1/BSF-3) [10,11].
OSM has unique and pleiotropic activities to regulate fetal liver
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adipocyte differentiation, and proliferation of some types of cancer
[12]. In mice, OSM binds the type II receptor, composed of the OSM
receptor (OSMR) and gp130, a receptor subunit common among
IL-6 subfamilies, and transmits signals via various routes including
the JAK/STAT and MAPK pathways [13].
In the present study, we found that OSM regulates the expres-
sion of Npnt via the JAK/STAT and MAPK signaling pathways, while
down-regulation of Npnt by OSM inﬂuences the inhibition of osteo-
blast differentiation in MC3T3-E1 cells, a mouse calvaria-derived
osteoblast progenitor cell line.
2. Results
We ﬁrst examined whether the expression of Npnt is regulated
by cytokines belonging to the IL-6 subfamily, such as OSM, LIF, IL-6,
and IL-11, using MC3T3-E1 cells. After treatment with 100 ng/ml of
each cytokine separately for 24 h, OSM was found to sharply
decrease the expression of NpntmRNA in the cells (Fig. 1). We also
examined the effects of OSM on Npnt gene expression using
another cell line, C2C12 cells from a mouse myoblast cell line.
OSM inhibited Npnt gene expression in C2C12 cells (Suppl.
Fig. 1). Next, to more precisely investigate the inﬂuence of OSM,
we treated MC3T3-E1 cells with a range of concentrations of
OSM for various time periods. As shown in Fig. 2A, OSM signiﬁ-
cantly induced down-regulation of Npnt mRNA expression in a
dose-dependent manner. Furthermore, when the cells were
exposed to OSM for at least 6 h, a strong reduction of Npnt
mRNA expression occurred in a time-dependent manner (Fig. 2B).0 **
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Fig. 1. Reduction of Npnt mRNA expression by OSM. MC3T3-E1 cells were treated
with 100 ng/ml of OSM, LIF, IL-6, or IL-11 for 24 h. Total cellular RNA was extracted,
and mRNA levels for Npnt and Gapdh were examined by real-time PCR analysis.
Results are shown as the mean ± SD from 3 samples as compared to the level at
0 ng/ml (without cytokine treatment). ⁄⁄P < 0.01, ⁄P < 0.05, Student’s t test relative
to the level without cytokine treatment.
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Fig. 2. Dose- and time-dependent effects of OSM on NpntmRNA expression. (A) Dose-dep
0, 0.1, 1, 10, or 100 ng/ml of OSM for 24 h. Results are shown as the mean ± SD from 3 sam
level with 0 ng/ml of OSM. §§P < 0.01, ANOVA relative to the level with 0.1 ng/ml of OSM. (
were treated with 10 ng/ml of OSM for 3, 6, 9, 12, or 24 h. Total cellular RNA was extracte
Results are shown as the mean ± SD from 3 samples as compared to the level at 0 h. ⁄⁄P <
time points.Since the binding of cytokines to their speciﬁc cell surface
receptor complexes is the start of cytokine signaling, we analyzed
the presence of receptors that mediate OSM signaling using RT-PCR
(Fig. 3A) and FACS (Fig. 3B) analyses. The RT-PCR shows that both
the OSM receptor (OSMR) and gp130 are expressed by MC3T3-E1
cells, while OSMR is located on the cell surface.
Following identiﬁcation of the OSM receptor complex in
MC3T3-E1 cells, we detected a signaling pathway utilized by
OSM in MC3T3-E1 cells. Phosphorylated STAT3 was revealed
by western blot analysis and that phosphorylation was reduced
by exposure to the JAK inhibitor (10 lM) (Fig. 3C). Based on those
results, the expression of Npnt in MC3T3-E1 cells treated with OSM
and the JAK inhibitor was analyzed using real-time PCR. As shown
in Fig. 3D, 10 lM of the JAK inhibitor blocked the inhibition
induced by 10 ng/ml of OSM and restored Npnt mRNA expression.
A previous study demonstrated that OSM stimulates MAPKs, such
as ERK1/2, p38 MAPK, and JNK, in bovine and human chondrocytes
[14]. To determine whether the MAPK pathway is involved in
down-regulation of Npnt gene expression by OSM, MC3T3-E1 cells
were treated with 10 lM of PD98059 [MAPK-ERK kinase (MEK)
inhibitor], SB203580 (p38 MAPK inhibitor), or SP600125 (JNK inhi-
bitor) following treatment with OSM at 10 ng/ml. Treatment with
PD98059, SB203580, and SP600125 inhibited the down-regulation
of Npnt gene expression by OSM (Fig. 4). These ﬁndings suggest
that the mechanism of regulation of Npnt expression by OSM
occurs via activation of MAPK pathway components and JAK/STAT.
To elucidate the relationship between inhibition of osteoblast
differentiation and reduction of Npnt gene expression by OSM,
we established Npnt over-expressing MC3T3-E1 cells. MC3T3-E1
cells were transfected with an Npnt expression vector containing
a neomycin resistant gene, then cultured in 3 mg/ml of medium
containing G418 for 1 week. To examine whether over-expression
of Npnt overcomes OSM-induced down-regulation of osteoblast
differentiation with BMP-2 which is an inducer of bone genesis,
MC3T3-E1 cells over-expressing Npnt were treated with OSM
(Fig. 5). Our results showed that over-expression of Npnt reduced
the level of OSM-induced inhibition of osteoblast differentiation
with BMP-2.
3. Discussion
The present novel ﬁndings demonstrated that OSM strongly
inhibits Npnt gene expression via the JAK/STAT and MAPK signaling
pathways, while OSM-induced inhibition of osteoblast differentia-
tion is overcomed by Npnt over-expression (Fig. 6).6 0 3 9 24 12 
** ** ** 
Culture period (h) 
႒no treatment 
႑OSM (10ng/ml) 
* 
endent effects of OSM on NpntmRNA expression. MC3T3-E1 cells were treated with
ples as compared to the level with 0 ng/ml of OSM. ⁄⁄P < 0.01, ANOVA relative to the
B) Time course analysis of effects of OSM on NpntmRNA expression. MC3T3-E1 cells
d, and mRNA levels for Npnt and Gapdhwere examined using real-time PCR analysis.
0.01, ⁄P < 0.05, Student’s t test as compared to the level with 0 ng/ml of OSM at each
OSM (10ng/ml)
᧩ ᧧
Osmr
gp130 
Gapdh
A 
OSM 
(10ng/ml) 
STAT3
pSTAT3
᧩ ᧧ ᧩
JAK inhibitor
(10µM)
᧧
᧩ ᧩ ᧧ ᧧
C 
B 
OSM (ng/ml)
JAK inhibitor (μM) 
0 
0 0 
10 10
10
0 
10
**
1 
2 
0 
N
pn
t/G
ap
dh
D 
Fluorescence intensity
0 102 103 104 105 
C
el
l C
ou
nt
500
1000
3 
** **
Fig. 3. Analysis of OSM signaling molecules. (A) RT-PCR analysis for presence of
OSM receptor (Osmr) and gp130 in MC3T3-E1 cells. With the present primers, the
size of the PCR products for Osmr and gp130 were 132 and 100 bp, respectively. (B)
MC3T3-E1 cells were subjected to ﬂow cytometry analysis for the presence of the
OSM receptor (OSMR) on the cell surface. The black area shows MC3T3-E1 cells
incubated with biotinylated anti-OSMR and FITC streptavidin. The gray area shows
MC3T3-E1 cells incubated with biotinylated anti-rat IgG2b j isotype and FITC
streptavidin. All cells were found positive for the OSM receptor. (C) OSM-induced
phosphorylation of STAT3 blocked by JAK inhibitor. MC3T3-E1 cells were pretreated
with 10 lM of the JAK inhibitor for 1 h, then treated with 10 ng/ml of OSM for
15 min. Total cellular proteins were extracted, and used to determine levels of
phosphorylated and total STAT3 [23]. (D) Inhibition of down-regulation of OSM-
induced Npnt expression by JAK inhibitor. MC3T3-E1 cells were treated with 10 ng/
ml of OSM and 10 lM of the JAK inhibitor for 24 h. Total cellular RNA was extracted,
and mRNA levels for Npnt and Gapdh were examined using real-time PCR analysis.
Results are shown as the mean ± SD from 3 samples as compared to the level with
0 ng/ml of OSM and the JAK inhibitor. ⁄⁄P < 0.01, Student’s t test relative to the level
with 0 ng/ml of the JAK inhibitor.
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Fig. 4. Inhibition of Npnt expression by OSM is regulated by ERK1/2. MC3T3-E1
cells were treated with 10 ng/ml of OSM and MAPK inhibitors (+PD; 10 lM
PD98059,+SB; 10 lM SB203580, or +SP; 10 lM SP600125) for 24 h. Total cellular
RNA was extracted, and mRNAs for Npnt and Gapdh were examined using real-time
PCR analysis. Results are shown as the mean ± SD from 6 samples as compared to
the level with 0 ng/ml of OSM and the MAPK inhibitors. ⁄⁄P < 0.01, Student’s t test
relative to the level without MAPK inhibitors.
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Fig. 5. Over-expression of Npnt recovers OSM-induced inhibition of osteoblast
differentiation. Npnt expressed vector or empty vector transfected MC3T3-E1 cells
were treated with BMP-2 (500 ng/ml) and with/without OSM (j OSM (100 ng/ml)
or h no treatment), then alkaline phosphatase (ALP) activity was determined after
2 days of treatment. Results are shown as the mean ± SD from 6 samples as
compared to the level in empty vector transfected MC3T3-E1 cells with 0 ng/ml of
OSM. ⁄⁄P < 0.01, ⁄P < 0.05, Student’s t test relative to level in empty vector
transfected MC3T3-E1 cells.
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Fig. 6. OSM strongly inhibits Npnt gene expression via the JAK/STAT and MAPK
signaling pathways, while OSM-induced inhibition of osteoblast differentiation is
recovered by Npnt over-expression in MC3T3-E1. RGD; motif of Arg-Gly-Asp
tripeptide.
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osteoblast differentiation. This Npnt-induced promotion of
osteoblastogenesis is regulated by TGF-b [5]. Furthermore, TNF-a,
a pro-inﬂammatory cytokine and inhibitory molecule of osteoblast
differentiation, was also shown to regulate Npnt expression via NF-
jB signaling [9]. OSM inﬂuences the differentiation and prolifera-
tion of osteoblasts [15], and Shih and Yen demonstrated thatOSM signiﬁcantly decreased cell proliferation and alkaline phos-
phatase activity, indicating the level of osteoblast differentiation,
in a dose-dependent manner [16]. On the other hand, other reports
noted that OSM induced alkaline phosphatase activity in MG63
cells obtained from a ﬁbroblastic osteosarcoma, suggesting that
its effect on osteoblast differentiation is dependent on the dif-
ferentiation status of the osteoblastic cell line being tested
[17–19]. Our results suggest that OSM-induced down-regulation
of Npntmay be, at least in part, involved in regulation of osteoblast
differentiation.
Previous studies demonstrated that OSM inhibits the activity of
MEF2A, a transcription factor, through JAK/STAT signaling pathway
in C2C12 cells [20], and the inhibition of MEF2A reduces the
expression of Kruppel-like factor (Klf) 2 in COS-7 cells [21].
Sunadome et al. demonstrated that expression of Npnt is regulated
by Klf2 via ERK5 activation in C2C12 cells during skeletal muscle
differentiation [22]. In the Npnt promoter, there are eight copies
of CACCC motifs which are Klf2 binding sites, and Npnt promoter
activity is directly activated by Klf2. From those studies, OSM-in-
duced down-regulation of Npnt can be explained by inhibition of
Klf2 and MEF2 which are regulated by JAK/STAT signaling path-
ways, but further experiments are required to fully elucidate this
mechanism.
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4.1. Cell cultures
MC3T3-E1 cells were maintained in MEMa with L-glutamine
and phenol red medium (Wako Pure Chemical Industries, Ltd.,
Cat. No. 135-15175), supplemented with 10% fetal bovine serum
(FBS) (Life Technologies, Cat. No. 10437) and 1% penicillin–strepto-
mycin at 37 C in a CO2 incubator (5% CO2, 95% air). To establish
Npnt over-expressing cells, MC3T3-E1 cells were transfected with
a Npnt-FLAG tagged vector or empty vector [2], then cultured in
10% FBS-MEMa containing 3 mg/ml G418 (Calbiochem-
NovaBiochem Corp., Cat. No. A1720-1G). C2C12 cells were main-
tained in DMEM (Wako Pure Chemical Industries, Ltd., Cat. No.
044-29765) supplemented with 15% FBS and 1% penicillin–strepto-
mycin at 37 C in a CO2 incubator. For the experiments, cells were
plated at 2  105 cells/well in 6-well plates (Thermo Scientiﬁc Inc.,
Cat. No. 140675).
4.2. Reagents
Mouse OSM (Cat. No. 495-MO-025), human LIF (Cat. No.
7734-LF-025), and mouse IL-11 (Cat. No. 418-ML-005), and human
BMP-2 (Cat. No. 355-BEC-010) were purchased from R&D Systems,
Inc., while human IL-6 (Cat. No. MAN0003501) came from Life
Technologies and a JAK inhibitor (pyridone 6 [2-(1,1-dimethy-
lethyl)-9-ﬂuoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-
7-one]) (Cat. No. 420099) from EMD Chemicals, Inc. PD98059 (Cat.
No. P215-1 mg), SB203580 (Cat. No. S8307-1 mg), and SP600125
(Cat. No. S5567-10 mg) were purchased from SIGMA.
4.3. RT-PCR
Total RNA was extracted using TRIzol reagent (Life
Technologies, Cat. No. 15596018), then reverse transcribed using
SuperScript III (Life Technologies, Cat. No. 18080-044). PCR was
performed with Taq polymerase (Promega, Cat. No. M7123) using
the following speciﬁc PCR primers.
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh):
50-GAAGGTCGGTGTGAACGGATTTGGC-30,
50-CATGTAGGCCATGAGGTCCACCAC-30.
Osm receptor (Osmr):
50-ATCCAAAGGCTCCGCAGGAC-30,
50-GTAAGGTTGCAGGTCAAGGC-30.
gp130:
50-ACATCGTGTGGAAGACCAAC-30,
50-ACTCTGATTTCAAAGTGTAG-30.
4.4. Quantitative real-time PCR
Quantitative real-time PCR was performed using a SYBR Green
Fast PCR system (Applied Biosystems) with the following speciﬁc
PCR primers.
Gapdh:
50-AAATGGTGAAGGTCGGTGTG-30,
50-TGAAGGGGTCGTTGATGG-30.
Nephronectin (Npnt):
50-CACGAGTAATTACGGTTGACAACAG-30,
50-CTGCCGTGGAATGAACACAT-30.4.5. Western blotting
Protein samples were collected using Sample Buffer Solution
with Reducing Reagent (6) for SDS–PAGE (Nacalai Tesque, Cat.
No. 09499-14) with a cell scraper (Corning Incorporated, Corning,
Cat. No. 3010), then electrophoresed on a 7.5% SDS polyacrylamide
gel, which was blotted onto a nitrocellulose membrane of the
iBlot2 Dry Blotting System (Life Technologies, Cat. No. IB21001).
The nitrocellulose membrane was soaked in iBind™ solution (Life
Technologies) for 24 h at 4 C, after which the blots were rinsed
with 10 ll of primary and secondary antibodies in iBind™ (Life
Technologies, Cat. No. SLF1000). Antibodies for phospho-STAT3
(Cat. No. 9131S) and STAT3 (Cat. No. 9139) were purchased from
Cell Signaling Technology, Inc. Anti-rabbit (Cat. No. NA934V) and
anti-mouse (Cat. No. NA931VS) IgG horseradish peroxidase linked
antibodies were purchased from GE Healthcare, and used as sec-
ondary antibodies to detect each of the primary antibodies. To
visualize the locations of the antigenic bands, peroxidase reactions
were developed using ECL Prime Western Blotting Detection
Reagent (GE Healthcare).
4.6. Flow cytometry analysis
After performing cell dissociation with Cell Dissociation
Solution (Sigma–Aldrich, Cat. No. C5914), MC3T3-E1 cells were
incubated with FcR Blocking Reagent for mouse (MACS Miltenyi
Biotec K.K., Cat. No. 120-003-855). Next, the cells were incubated
with biotinylated rat IgG2b j isotype as a control (Becton,
Dickinson and Company, Cat No. 553987) or a biotinylated anti-
mouse OSM receptor (OSMR) antibody (Medical & Biological
Laboratories CO., Ltd., Cat. No. D059-3), followed by incubation
with FITC streptavidin (Medical & Biological Laboratories CO.,
Ltd., Cat. No. 554060). Fluorescent immunostained samples were
examined using FACSVerse Ver. 1.0 Suite 1.0.3 (Becton, Dickinson
and Company), and data acquisition and analysis were performed
using FACSuite™ (Becton, Dickinson and Company).
4.7. ALP (alkaline phosphatase) activity
ALP activity in the cell lysates was determined following
incubation with the substrate p-nitrophenylphosphate (Wako
Pure Chemical Industries, Ltd., Cat. No. 149–02342) in buffer (pH
10) containing 0.1 M 2-amino-2-methyl-1-propanol and 2 mM
MgCl2.
4.8. Statistical analysis
All results are expressed as means ± SD. In Fig. 2A and Suppl.
Fig. 1, statistical analysis was performed using one-way ANOVA.
In other results, statistical analysis was performed using a two-
tailed Student’s t test. A P value of P < 0.05 was considered sta-
tistically signiﬁcant.
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